Skip to Main Content

Robert L. Ilaria

Perlmutter Cancer Center

Clinical Assistant Professor, Department of Medicine

Positions

Clinical Assistant Professor, Department of Medicine at NYU Grossman School of Medicine

Is this your profile?
Edit profile

Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

Jones, Robin L; Mo, Gary; Baldwin, John R; Peterson, Patrick M; Ilaria, Robert L; Conti, Ilaria; Cronier, Damien M; Tap, William D

Cancer chemotherapy & pharmacology. 2019 01; 83(1):191-199

Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Hakenberg, Oliver W; Perez-Gracia, Jose Luis; Castellano, Daniel; Demkow, Tomasz; Ali, Tarek; Caffo, Orazio; Heidenreich, Axel; Schultze-Seemann, Wolfgang; Sautois, Brieuc; Pavlik, Ivan; Qin, Amy; Novosiadly, Ruslan D; Shahir, Ashwin; Ilaria, Robert; Nippgen, Johannes

European journal of cancer (1990). 2019 Jan; 107:186-195

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

McGuire, William P; Penson, Richard T; Gore, Martin; Herraez, Antonio Casado; Peterson, Patrick; Shahir, Ashwin; Ilaria, Robert

BMC cancer. 2018 Dec 27; 18(1):1292

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

Mo, Gary; Baldwin, John R; Luffer-Atlas, Debra; Ilaria, Robert L; Conti, Ilaria; Heathman, Michael; Cronier, Damien M

Clinical pharmacokinetics. 2018 03; 57(3):355-365

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

Gerber, David E; Swanson, Paul; Lopez-Chavez, Ariel; Wong, Lucas; Dowlati, Afshin; Pennell, Nathan A; Cronier, Damien M; Qin, Amy; Ilaria, Robert; Cosaert, Jan; Shahir, Ashwin; Baggstrom, Maria Q

Lung cancer. 2017 09; 111:108-115

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Vadhan-Raj, Saroj; Abonour, Rafat; Goldman, Jonathan W; Smith, David A; Slapak, Christopher A; Ilaria, Robert L; Tiu, Ramon V; Wang, Xuejing; Callies, Sophie; Cox, Joanne; Tuttle, Jay L; Lau, Yiu-Keung; Roeland, Eric J

Journal of hematology & oncology. 2017 03 21; 10(1):73

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Tap, William D; Jones, Robin L; Van Tine, Brian A; Chmielowski, Bartosz; Elias, Anthony D; Adkins, Douglas; Agulnik, Mark; Cooney, Matthew M; Livingston, Michael B; Pennock, Gregory; Hameed, Meera R; Shah, Gaurav D; Qin, Amy; Shahir, Ashwin; Cronier, Damien M; Ilaria, Robert; Conti, Ilaria; Cosaert, Jan; Schwartz, Gary K

Lancet. 2016 Jul 30; 388(10043):488-97

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

Jotte, Robert M; Von Hoff, Daniel D; Braiteh, Fadi; Becerra, Carlos R; Richards, Donald A; Smith, David A; Garbo, Lawrence; Stephenson, Joe; Conkling, Paul R; Robert-Vizcarrondo, Francisco; Chen, Jian; Turner, P Kellie; Chow, Kay Hoong; Tai, D Fritz; Ilaria, Robert

Investigational new drugs. 2015 Feb; 33(1):148-58

See All Publications (32)